Overwijk W W, Restifo N P
Trends Immunol. 2001 Jan;22(1):5-7. doi: 10.1016/s1471-4906(00)01793-2.
With the identification of tumor antigens and a knowledge of how to vaccinate against them, the field of tumor immunology faces new challenges. In this article, the authors argue that successful immunotherapies of the future will activate anti-tumor T cells without inducing their anergy or apoptotic death.
随着肿瘤抗原的鉴定以及如何针对这些抗原进行疫苗接种的知识的掌握，肿瘤免疫学领域面临着新的挑战。在本文中，作者认为未来成功的免疫疗法将激活抗肿瘤T细胞，而不会诱导其无反应性或凋亡死亡。
